Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial
JAAD. 2024. Epub ahead of print DOI: 10.1016/j.jaad.2024.09.074
Werth et al. demonstrated that iberdomide significantly improved cutaneous lupus erythematosus (CLE) outcomes, particularly in subacute and chronic CLE patients, by reducing Cutaneous Lupus Area and Severity Index Activity (CLASI-A) scores. The study showed continued efficacy through 24 weeks, with the 0.45 mg dose providing the greatest improvement in patients with severe baseline scores, and iberdomide was well-tolerated over 104 weeks.
Keywords:
December 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42391
Phase II trial results of deucravacitinib support the potential benefits of TYK2 inhibition in SLE.
Keywords:
June 2022
Biological impact of iberdomide in patients with active systemic lupus erythematosus
doi: 10.1136/annrheumdis-2022-222212
Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.
Keywords:
March 2022
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
Kidney Int Rep. 2021;7(3):516-525 doi: 10.1056/NEJMoa2106535
This Phase 2 trial evaluated iberdomide in patients with moderate-to-severe systemic lupus erythematosus (SLE).